Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with Tough-to-Treat leukemia

NCT ID NCT03591510

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing the safety and effectiveness of adding a drug called midostaurin to standard chemotherapy for children newly diagnosed with a specific genetic type of acute myeloid leukemia (AML). It involves 22 children and aims to see if this combination can better control the cancer and keep it from coming back. The trial has two parts: first finding the right dose, and then seeing how well that dose works.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FLT3-MUTATED ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Prague, 150 06, Czechia

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Pavia, PV, 27100, Italy

  • Novartis Investigative Site

    Roma, RM, 00165, Italy

  • Novartis Investigative Site

    Torino, TO, 10126, Italy

  • Novartis Investigative Site

    Naples, 80122, Italy

  • Novartis Investigative Site

    Osaka, 5340021, Japan

  • Novartis Investigative Site

    Amman, 11941, Jordan

  • Novartis Investigative Site

    Krakow, 30-663, Poland

  • Novartis Investigative Site

    Moscow, 117198, Russia

  • Novartis Investigative Site

    Ljubljana, 1000, Slovenia

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Adana, Adana, 1330, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.

FLT3-MUTATED ACUTE MYELOID LEUKEMIA